Analysis of MTX-3937-treated human peripheral NK cells

Siglec-9 has been of particular interest for their potential as immune checkpoints. Here, we employed docking-based virtual screening combined with bio-layer interferometry assays to identify a potential Siglec-9 inhibitor, MTX-3937. Analysis showed that MTX-3937-treatment significantly enhanced the production of IFN-?, TNF-a, perforin and CD107a in human NK cells. Consistently, MTX-3937 largely promoted NK cells tumor killing activities both in vitro and in vivo. In mechanism, MTX-3937 inhibited the phosphorylation level of SHP-1/2 in NK92 cells. Overall design: To globally characterize MTX-3937-mediated improvement of NK cell functions, we assessed the transcriptional profiles of MTX-3937- and DMSO-treated human peripheral NK cells from healthy donors.